1
|
Crocchiolo R, Frassati C, Gallina AM, Pedini P, Maioli S, Veronese L, Pani A, Scaglione F, D'Amico F, Crucitti L, Sacchi N, Rossini S, Picard C. Strong humoral response after Covid-19 vaccination correlates with the common HLA allele A*03:01 and protection from breakthrough infection. HLA 2024; 103:e15421. [PMID: 38433722 DOI: 10.1111/tan.15421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2023] [Revised: 02/14/2024] [Accepted: 02/16/2024] [Indexed: 03/05/2024]
Abstract
Few data exist on the role of genetic factors involving the HLA system on response to Covid-19 vaccines. Moving from suggestions of a previous study investigating the association of some HLA alleles with humoral response to BNT162b2, we here compared the HLA allele frequencies among weak (n = 111) and strong (n = 123) responders, defined as those healthcare workers with the lowest and the highest anti-Spike antibody levels after vaccination. Individuals with clinical history of Covid-19 or positive anti-nucleocapside antibodies were excluded. We found the common HLA-A*03:01 allele as an independent predictor of strong humoral response (OR = 12.46, 95% CI: 4.41-35.21, p < 0.0001), together with younger age of vaccines (p = 0.004). Correlation between antibody levels and protection from breakthrough infection has been observed, with a 2-year cumulative incidence of 42% and 63% among strong and weak responders, respectively (p = 0.03). Due to the high frequency of HLA-A*03:01 and the need for seasonal vaccinations against SARS-CoV-2 mutants, our findings provide useful information about the inter-individual differences observed in humoral response after Covid-19 vaccine and might support further studies on the next seasonal vaccines.
Collapse
Affiliation(s)
- Roberto Crocchiolo
- Dipartimento dei Servizi, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
| | | | - Anna Maria Gallina
- Italian Bone Marrow Donor Registry, E.O. Ospedali Galliera Genova, Genova, Italy
| | | | | | - Luca Veronese
- Dipartimento dei Servizi, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
| | - Arianna Pani
- Dipartimento dei Servizi, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
| | - Francesco Scaglione
- Dipartimento dei Servizi, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
| | - Federico D'Amico
- Dipartimento dei Servizi, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
| | - Lara Crucitti
- Hematology Department, Azienda Sanitaria Provinciale di Trapani, Castelvetrano, Italy
| | - Nicoletta Sacchi
- Italian Bone Marrow Donor Registry, E.O. Ospedali Galliera Genova, Genova, Italy
| | - Silvano Rossini
- Dipartimento dei Servizi, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy
| | | |
Collapse
|
2
|
Alizadeh M, Frassati C, Walencik A, Picard C, Pedini P. Characterization of 43 novel HLA-H alleles. HLA 2024; 103:e15203. [PMID: 37632724 DOI: 10.1111/tan.15203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2023] [Revised: 08/09/2023] [Accepted: 08/11/2023] [Indexed: 08/28/2023]
Abstract
Forty-three novel HLA-H alleles, including 32 identified in cohorts of French donors for Hematopoietic Stem Cell Transplantation, have been characterized by Next-Generation Sequencing (NGS) using a long range PCR approach. A phylogenetic study confirms three main HLA-H clades.
Collapse
Affiliation(s)
- Mehdi Alizadeh
- National Reagent Production Laboratory, Établissement Français du Sang Bretagne, Rennes, France
| | - Coralie Frassati
- Immunogenetics Laboratory, Établissement Français du Sang PACA Corse, Marseille, France
- ADES UMR, Aix Marseille Univ, Marseille, France
| | - Alexandre Walencik
- Imunogenetics Laboratory, Établissement Français du Sang, Nantes, France
| | - Christophe Picard
- Immunogenetics Laboratory, Établissement Français du Sang PACA Corse, Marseille, France
- ADES UMR, Aix Marseille Univ, Marseille, France
| | - Pascal Pedini
- Immunogenetics Laboratory, Établissement Français du Sang PACA Corse, Marseille, France
- ADES UMR, Aix Marseille Univ, Marseille, France
| |
Collapse
|
3
|
Pedini P, Hubert L, Baudey JB, Etienne JM, Basire A, Vey N, Chiaroni J, Chabrières C, Ladaique P, Picard C. Comparison of HLA antibody identification methods for the selection of platelet products for HLA-mediated platelet refractory patients. HLA 2024; 103:e15276. [PMID: 37947374 DOI: 10.1111/tan.15276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Revised: 09/20/2023] [Accepted: 10/19/2023] [Indexed: 11/12/2023]
Abstract
In an ineffective transfusion context, solid-phase immunoassays using the Luminex platform for the detection and characterization of HLA antibodies are currently used to select HLA-compatible platelet products. A new HLA antibody identification method, the HISTO SPOT® HLA AB test (BAG Health care GmbH, Lich, Germany), based on the detection of antibodies directed against a recombinant single antigen (SA) by colored spots detected by HISTO MATCH HLA AB module software, runs fully automated on the MR.SPOT®. The aim of this study was to compare the ability of the HISTO SPOT HLA AB and C1qScreen™ (C1q SAB) assays with that of the Labscreen single antigen class I (OL SAB) assay to detect anti-HLA class I antibodies in 56 serum samples from 54 platelet refractory acute myeloid leukemia patients who received HLA mismatch platelet concentrates at a single oncohematology center. In total, 1414 class I specificities, 433 HLA-A and 981 HLA-B, were detected by the OL SAB test. The mean fluorescence intensity (MFI) was >5000 for 874 antigens and <5000 for 655 antigens. The HISTO SPOT® HLA AB and C1q SAB tests identified 85% and 79% of OL SA-detected antigens with an MFI >5000, respectively, but did not identify 34% and 44% of OL SAB-detected antigens, highlighting the lower sensitivity of these techniques. Interestingly, the donor-specific antibodies (DSAs) identified by the HISTO SPOT® HLA AB and C1q SAB assays reacted against HLA mismatch platelet concentrates with the same specificity (86%) and positive predictive (77%) value as in the OL SAB test when the MFI threshold was >2000 for DSA detection. Although the HISTO SPOT® HLA AB test is less sensitive than the OL SAB test, this test could be used for the selection of HLA-compatible platelet products.
Collapse
Affiliation(s)
- Pascal Pedini
- Immunogenetic and Histocompatibility Laboratory, EFS PACC, Marseille, France
- ADES UMR, Aix Marseille Univ, Marseille, France
| | - Lucas Hubert
- Immunogenetic and Histocompatibility Laboratory, EFS PACC, Marseille, France
| | | | - Jean-Michel Etienne
- Immunohematology Laboratory, Institut Paoli-calmettes, EFS PACC, Marseille, France
| | - Agnes Basire
- Immunogenetic and Histocompatibility Laboratory, EFS PACC, Marseille, France
| | - Norbert Vey
- Onco-Hématology Department, Institut Paoli-calmettes, Marseille, France
| | | | - Corinne Chabrières
- Immunohematology Laboratory, Institut Paoli-calmettes, EFS PACC, Marseille, France
| | - Patrick Ladaique
- Onco-Hématology Department, Institut Paoli-calmettes, Marseille, France
| | - Christophe Picard
- Immunogenetic and Histocompatibility Laboratory, EFS PACC, Marseille, France
- ADES UMR, Aix Marseille Univ, Marseille, France
| |
Collapse
|
4
|
Pedini P, Hubert L, Carlini F, Baudey JB, Tous A, Jordier F, Basire A, Bagnis C, Reynaud-Gaubert M, Coiffard B, Chiaroni J, Silvy M, Picard C. Low Prevalence of HLA-G Antibodies in Lung Transplant Patients Detected using MAIPA-Adapted Protocol. Int J Mol Sci 2023; 24:16479. [PMID: 38003669 PMCID: PMC10671704 DOI: 10.3390/ijms242216479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2023] [Revised: 11/12/2023] [Accepted: 11/16/2023] [Indexed: 11/26/2023] Open
Abstract
Lung transplantation is often complicated by acute and/or chronic rejection leading to graft-function loss. In addition to the HLA donor-specific antibodies (HLA-DSA), a few autoantibodies are correlated with the occurrence of these complications. Recently, antibodies directed against non-classical HLA molecules, HLA-G, -E, and -F have been detected in autoimmune diseases, like systemic lupus erythematosus. Non-classical HLA molecules are crucial in the immunological acceptance of the lung graft, and some of their isoforms, like HLA-G*01:04 and -G*01:06, are associated with a negative clinical outcome. The aim of this study is to determine the frequency of detection of HLA-G antibodies in lung transplant recipients (LTRs) and their impact on the occurrence of clinical complications. After incubating the cell lines SPI-801, with and without three different HLA-G isoform expression, with sera from 90 healthy blood donors and 35 LTRs (before and after transplantation), HLA-G reactivity was revealed using reagents from commercial monoclonal antibody immobilization of platelet antigen assay (MAIPA ApDIA®). Only one serum from one blood donor had specific reactivity against the HLA-G transduced lines. Non-specific reactivity in many sera from LTRs was observed with transduced- and wild-type cell lines, which may suggest recognition of an autoantigen expressed by the SPI-801 cell line. In conclusion, this study allowed the development of a specific detection tool for non-denatured HLA-G antibodies. These antibodies seem uncommon, both in healthy subjects and in complicated LTRs. This study should be extended to patients suffering from autoimmune diseases as well as kidney and heart transplant recipients.
Collapse
Affiliation(s)
- Pascal Pedini
- Immunogenetics Laboratory, Etablissement Français du Sang, 13005 Marseille, France (C.P.)
- ADES UMR 7268, Aix Marseille University, 13005 Marseille, France; (A.T.)
| | - Lucas Hubert
- Immunogenetics Laboratory, Etablissement Français du Sang, 13005 Marseille, France (C.P.)
| | | | - Jean Baptiste Baudey
- Immunogenetics Laboratory, Etablissement Français du Sang, 13005 Marseille, France (C.P.)
| | - Audrey Tous
- ADES UMR 7268, Aix Marseille University, 13005 Marseille, France; (A.T.)
| | - Francois Jordier
- ADES UMR 7268, Aix Marseille University, 13005 Marseille, France; (A.T.)
| | - Agnès Basire
- Immunogenetics Laboratory, Etablissement Français du Sang, 13005 Marseille, France (C.P.)
| | - Claude Bagnis
- ADES UMR 7268, Aix Marseille University, 13005 Marseille, France; (A.T.)
| | | | - Benjamin Coiffard
- Lung Transplant Department, Aix-Marseille University, APHM, 13015 Marseille, France
| | - Jacques Chiaroni
- ADES UMR 7268, Aix Marseille University, 13005 Marseille, France; (A.T.)
| | - Monique Silvy
- ADES UMR 7268, Aix Marseille University, 13005 Marseille, France; (A.T.)
| | - Christophe Picard
- Immunogenetics Laboratory, Etablissement Français du Sang, 13005 Marseille, France (C.P.)
- ADES UMR 7268, Aix Marseille University, 13005 Marseille, France; (A.T.)
| |
Collapse
|
5
|
Frassati C, Basire A, Chiaroni J, Picard C, Pedini P. Characterization of the novel HLA-B*07:482 allele using next-generation sequencing methods. HLA 2023; 102:619-620. [PMID: 37602773 DOI: 10.1111/tan.15195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2023] [Revised: 08/02/2023] [Accepted: 08/07/2023] [Indexed: 08/22/2023]
Abstract
HLA-B*07:482 differs from HLA-B*07:02:01:01 allele by one nucleotide substitution in codon 285 in exon 5.
Collapse
Affiliation(s)
- Coralie Frassati
- Immunogenetics Laboratory, Etablissement français du Sang PACA Corse, Marseille, France
- ADES UMR, Aix Marseille University, Marseille, France
| | - Agnes Basire
- Immunogenetics Laboratory, Etablissement français du Sang PACA Corse, Marseille, France
| | - Jacques Chiaroni
- Immunogenetics Laboratory, Etablissement français du Sang PACA Corse, Marseille, France
- ADES UMR, Aix Marseille University, Marseille, France
| | - Christophe Picard
- Immunogenetics Laboratory, Etablissement français du Sang PACA Corse, Marseille, France
- ADES UMR, Aix Marseille University, Marseille, France
| | - Pascal Pedini
- Immunogenetics Laboratory, Etablissement français du Sang PACA Corse, Marseille, France
- ADES UMR, Aix Marseille University, Marseille, France
| |
Collapse
|
6
|
Pedini P, Brami B, Walencik A, Frassati C, Picard C. Characterization of the novel HLA-A*33:246 allele using next-generation sequencing. HLA 2023; 102:617-619. [PMID: 37602739 DOI: 10.1111/tan.15194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2023] [Revised: 08/02/2023] [Accepted: 08/07/2023] [Indexed: 08/22/2023]
Abstract
HLA-A*33:246 differs from HLA-A*33:01:01:01 allele by one nucleotide substitution in codon 135 in exon 3.
Collapse
Affiliation(s)
- Pascal Pedini
- Immunogenetics Laboratory, Etablissement français du Sang PACA Corse, Marseille, France
- ADES UMR, Aix Marseille University, Marseille, France
| | - Beila Brami
- Immunogenetics Laboratory, Etablissement français du Sang PACA Corse, Marseille, France
| | - Alexandre Walencik
- Imunogenetics Laboratory, Etablissement français du Sang, Nantes, France
| | - Coralie Frassati
- Immunogenetics Laboratory, Etablissement français du Sang PACA Corse, Marseille, France
- ADES UMR, Aix Marseille University, Marseille, France
| | - Christophe Picard
- Immunogenetics Laboratory, Etablissement français du Sang PACA Corse, Marseille, France
- ADES UMR, Aix Marseille University, Marseille, France
| |
Collapse
|
7
|
Raz M, Demortier J, Frassati C, Picard C, Pedini P. The novel HLA-DQA1*03:01:12 allele identified using next-generation sequencing in a Melanesian individual. HLA 2023; 102:643-645. [PMID: 37528672 DOI: 10.1111/tan.15175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2023] [Revised: 07/19/2023] [Accepted: 07/22/2023] [Indexed: 08/03/2023]
Abstract
HLA-DQA1*03:01:12 differs from HLA-DQA1*03:01:01:01 by one nucleotide substitution in codon 21 in exon 2.
Collapse
Affiliation(s)
- Maxime Raz
- Service de Transfusion Sanguine, Centre hospitalier de Nouméa, Noumea, New Caledonia
| | - Justine Demortier
- Service de Transfusion Sanguine, Centre hospitalier de Nouméa, Noumea, New Caledonia
| | - Coralie Frassati
- Immunogenetics Laboratory, Etablissement français du Sang PACA Corse, Marseille, France
- ADES UMR, Aix Marseille Univ, Marseille, France
| | - Christophe Picard
- Immunogenetics Laboratory, Etablissement français du Sang PACA Corse, Marseille, France
- ADES UMR, Aix Marseille Univ, Marseille, France
| | - Pascal Pedini
- Immunogenetics Laboratory, Etablissement français du Sang PACA Corse, Marseille, France
- ADES UMR, Aix Marseille Univ, Marseille, France
| |
Collapse
|
8
|
Bernit E, Jean E, Marlot B, Laget L, Izard C, Dettori I, Beley S, Gautier I, Agouti I, Frassati C, Pedini P, Picard C, Paganini J, Chiaroni J, Di Cristofaro J. HLA-F and LILRB1 Genetic Polymorphisms Associated with Alloimmunisation in Sickle Cell Disease. Int J Mol Sci 2023; 24:13591. [PMID: 37686397 PMCID: PMC10487752 DOI: 10.3390/ijms241713591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2023] [Revised: 08/25/2023] [Accepted: 08/31/2023] [Indexed: 09/10/2023] Open
Abstract
Red blood cell (RBC) transfusion remains a critical component in caring for the acute and chronic complications of sickle cell disease (SCD). Patient alloimmunisation is the main limitation of transfusion, which can worsen anaemia and lead to delayed haemolytic transfusion reaction or transfusion deadlock. Although biological risk factors have been identified for immunisation, patient alloimmunisation remains difficult to predict. We aimed to characterise genetic alloimmunisation factors to optimise the management of blood products compatible with extended antigen matching to ensure the self-sufficiency of labile blood products. Considering alloimmunisation in other clinical settings, like pregnancy and transplantation, many studies have shown that HLA Ib molecules (HLA-G, -E, and -F) are involved in tolerance mechanism; these molecules are ligands of immune effector cell receptors (LILRB1, LILRB2, and KIR3DS1). Genetic polymorphisms of these ligands and receptors have been linked to their expression levels and their influence on inflammatory and immune response modulation. Our hypothesis was that polymorphisms of HLA Ib genes and of their receptors are associated with alloimmunisation susceptibility in SCD patients. The alloimmunisation profile of thirty-seven adult SCD patients was analysed according to these genetic polymorphisms and transfusion history. Our results suggest that the alloimmunisation of SCD patients is linked to both HLA-F and LILRB1 genetic polymorphisms located in their regulatory region and associated with their protein expression level.
Collapse
Affiliation(s)
- Emmanuelle Bernit
- Unité Transversale de la Drépanocytose, Centre de Référence Antilles-Guyane pour la Drépanocytose, les Thalassémies et les Maladies Constitutives du Globule Rouge et de l’Erythropoïèse, CHU Guadeloupe, 97110 Pointe à Pitre, France
| | - Estelle Jean
- Centre de Référence pour la Drépanocytose, les Thalassémies et les Maladies Constitutives du Globule Rouge et de l’Erythropoïèse, Assistance Publique des Hôpitaux de Marseille, 13005 Marseille, France
| | - Bastien Marlot
- UMR7268, ADES, EFS, CNRS, Aix Marseille University, 13003 Marseille, France
| | - Laurine Laget
- Etablissement Français du Sang PACA Corse, 13001 Marseille, France
| | - Caroline Izard
- Etablissement Français du Sang PACA Corse, 13001 Marseille, France
| | - Isabelle Dettori
- Etablissement Français du Sang PACA Corse, 13001 Marseille, France
| | - Sophie Beley
- UMR7268, ADES, EFS, CNRS, Aix Marseille University, 13003 Marseille, France
| | - Isabelle Gautier
- Centre de Référence pour la Drépanocytose, les Thalassémies et les Maladies Constitutives du Globule Rouge et de l’Erythropoïèse, Assistance Publique des Hôpitaux de Marseille, 13005 Marseille, France
| | - Imane Agouti
- Centre de Référence pour la Drépanocytose, les Thalassémies et les Maladies Constitutives du Globule Rouge et de l’Erythropoïèse, Assistance Publique des Hôpitaux de Marseille, 13005 Marseille, France
| | - Coralie Frassati
- UMR7268, ADES, EFS, CNRS, Aix Marseille University, 13003 Marseille, France
- Etablissement Français du Sang PACA Corse, 13001 Marseille, France
| | - Pascal Pedini
- UMR7268, ADES, EFS, CNRS, Aix Marseille University, 13003 Marseille, France
- Etablissement Français du Sang PACA Corse, 13001 Marseille, France
| | - Christophe Picard
- UMR7268, ADES, EFS, CNRS, Aix Marseille University, 13003 Marseille, France
- Etablissement Français du Sang PACA Corse, 13001 Marseille, France
| | | | - Jacques Chiaroni
- UMR7268, ADES, EFS, CNRS, Aix Marseille University, 13003 Marseille, France
- Etablissement Français du Sang PACA Corse, 13001 Marseille, France
| | - Julie Di Cristofaro
- UMR7268, ADES, EFS, CNRS, Aix Marseille University, 13003 Marseille, France
- Etablissement Français du Sang PACA Corse, 13001 Marseille, France
| |
Collapse
|
9
|
Pedini P, Laget L, Izard C, Menanteau C, Beley S, Granier T, Picard C, Bailly P, Chiaroni J, Mazieres S, Peyrard T, Silvy M. Identification of an Alu-mediated 5.7-kb deletion of the LU gene in a pregnant Moroccan woman with anti-Lu3. Blood Transfus 2023; 21:385-389. [PMID: 36346881 PMCID: PMC10497386 DOI: 10.2450/2022.0200-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 05/04/2022] [Accepted: 09/15/2022] [Indexed: 06/16/2023]
Affiliation(s)
- Pascal Pedini
- EFS PACA-Corse, Marseille, France
- Aix Marseille Univ, CNRS, EFS, ADES, Marseille, France
| | - Laurine Laget
- EFS PACA-Corse, Marseille, France
- Aix Marseille Univ, CNRS, EFS, ADES, Marseille, France
| | - Caroline Izard
- EFS PACA-Corse, Marseille, France
- Aix Marseille Univ, CNRS, EFS, ADES, Marseille, France
| | - Cécile Menanteau
- EFS Ile de France, Centre National de Référence pour les Groupes Sanguins (CNRGS), Paris, France
| | - Sophie Beley
- EFS PACA-Corse, Marseille, France
- Aix Marseille Univ, CNRS, EFS, ADES, Marseille, France
| | - Thomas Granier
- EFS PACA-Corse, Marseille, France
- Aix Marseille Univ, CNRS, EFS, ADES, Marseille, France
| | - Christophe Picard
- EFS PACA-Corse, Marseille, France
- Aix Marseille Univ, CNRS, EFS, ADES, Marseille, France
| | - Pascal Bailly
- EFS PACA-Corse, Marseille, France
- Aix Marseille Univ, CNRS, EFS, ADES, Marseille, France
| | - Jacques Chiaroni
- EFS PACA-Corse, Marseille, France
- Aix Marseille Univ, CNRS, EFS, ADES, Marseille, France
| | | | - Thierry Peyrard
- EFS Ile de France, Centre National de Référence pour les Groupes Sanguins (CNRGS), Paris, France
- UMR_S1134, BIGR, Inserm, Université Paris Cité, Paris, France
| | - Monique Silvy
- EFS PACA-Corse, Marseille, France
- Aix Marseille Univ, CNRS, EFS, ADES, Marseille, France
| |
Collapse
|
10
|
Ladaique P, Etienne JM, Pedini P, Chiaroni J, Vey N, Picard C, Chabrieres C. Therapeutic efficacy of platelet transfusion treated with amotosalen/UVA pathogen inactivation technology (INTERCEPT TM Blood System) in acute myeloid leukemia patients undergoing chemotherapy with curative intent: a single center experience. Blood Transfus 2023; 21:400-408. [PMID: 36795348 PMCID: PMC10497385 DOI: 10.2450/2023.0143-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 06/16/2022] [Accepted: 11/25/2022] [Indexed: 02/17/2023]
Abstract
BACKGROUND The INTERCEPTTM Blood System (Intercept Blood System, Cerus Europe BV, Amersfoort, the Netherlands) has been used to reduce or inactivate pathogen load in platelet concentrates in France for three years. MATERIALS AND METHODS After comparing the transfusion efficiency between pathogen-reduced platelets (PR_PLT) and untreated platelet products (U_PLT), our single-center observational study assessed the effectiveness of PR_PLT for the prevention of bleeding and for therapeutic treatment of WHO grade 2 bleeding in 176 patients undergoing chemotherapy with curative intent for acute myeloid leukemia (AML). The main endpoints were the 24-hour (h) corrected count increment (24h_CCI) after each transfusion, and time to next transfusion. RESULTS Whereas the transfused doses tended to be higher in the PR_PLT group compared to U_PLT, there was a significant difference in intertransfusion interval (ITI) and 24h_CCI. In prophylactic transfusions, PR_PLT transfusions of >0.65×1011/10 kg, regardless of the age of the product (day 2 to day 5), resulted in a 24h_CCI similar to that of the untreated platelet product; this meant the patient could be transfused at least every 48h. In contrast, most PR_PLT transfusions of <0.55×1011/10 kg did not achieve a transfusion interval of 48h. In the context of WHO grade 2 bleeding, PR_PLT transfusions >0.65×1011/10 kg and storage of less than 4 days seems more effective in stopping bleeding. DISCUSSION These results, which must be confirmed by prospective studies, indicate the need for vigilance regarding the quantity and quality of PR_PLT products used to treat patients at risk of bleeding crisis. Future prospective studies are needed to confirm these findings.
Collapse
Affiliation(s)
- Patrick Ladaique
- Hematology Department, Institut Paoli-Calmettes, Marseille, France
| | | | - Pascal Pedini
- EFS PACA-Corse, Marseille, France
- Aix Marseille Université, CNRS, EFS, ADES, Marseille, France
| | - Jacques Chiaroni
- EFS PACA-Corse, Marseille, France
- Aix Marseille Université, CNRS, EFS, ADES, Marseille, France
| | - Norbert Vey
- Hematology Department, Institut Paoli-Calmettes, Marseille, France
- Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, CNRS, Aix-Marseille Université, Marseille, France
| | - Christophe Picard
- EFS PACA-Corse, Marseille, France
- Aix Marseille Université, CNRS, EFS, ADES, Marseille, France
| | | |
Collapse
|
11
|
Sleiman A, Lalanne K, Vianna F, Perrot Y, Richaud M, SenGupta T, Cardot-Martin M, Pedini P, Picard C, Nilsen H, Galas S, Adam-Guillermin C. Targeted Central Nervous System Irradiation with Proton Microbeam Induces Mitochondrial Changes in Caenorhabditis elegans. Biology (Basel) 2023; 12:839. [PMID: 37372124 DOI: 10.3390/biology12060839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/08/2023] [Revised: 06/06/2023] [Accepted: 06/07/2023] [Indexed: 06/29/2023]
Abstract
Fifty percent of all patients with cancer worldwide require radiotherapy. In the case of brain tumors, despite the improvement in the precision of radiation delivery with proton therapy, studies have shown structural and functional changes in the brains of treated patients with protons. The molecular pathways involved in generating these effects are not completely understood. In this context, we analyzed the impact of proton exposure in the central nervous system area of Caenorhabditis elegans with a focus on mitochondrial function, which is potentially implicated in the occurrence of radiation-induced damage. To achieve this objective, the nematode C. elegans were micro-irradiated with 220 Gy of protons (4 MeV) in the nerve ring (head region) using the proton microbeam, MIRCOM. Our results show that protons induce mitochondrial dysfunction, characterized by an immediate dose-dependent loss of the mitochondrial membrane potential (ΔΨm) associated with oxidative stress 24 h after irradiation, which is itself characterized by the induction of the antioxidant proteins in the targeted region, observed using SOD-1::GFP and SOD-3::GFP strains. Moreover, we demonstrated a two-fold increase in the mtDNA copy number in the targeted region 24 h after irradiation. In addition, using the GFP::LGG-1 strain, an induction of autophagy in the irradiated region was observed 6 h following the irradiation, which is associated with the up-regulation of the gene expression of pink-1 (PTEN-induced kinase) and pdr-1 (C. elegans parkin homolog). Furthermore, our data showed that micro-irradiation of the nerve ring region did not impact the whole-body oxygen consumption 24 h following the irradiation. These results indicate a global mitochondrial dysfunction in the irradiated region following proton exposure. This provides a better understanding of the molecular pathways involved in radiation-induced side effects and may help in finding new therapies.
Collapse
Affiliation(s)
- Ahmad Sleiman
- Institut de Radioprotection et de Sûreté Nucléaire, IRSN, PSE-SANTE/SDOS/LMDN, Cadarache, 13115 Saint-Paul-lez-Durance, France
| | - Kévin Lalanne
- Institut de Radioprotection et de Sûreté Nucléaire, IRSN, PSE-SANTE/SDOS/LMDN, Cadarache, 13115 Saint-Paul-lez-Durance, France
| | - François Vianna
- Institut de Radioprotection et de Sûreté Nucléaire, IRSN, PSE-SANTE/SDOS/LMDN, Cadarache, 13115 Saint-Paul-lez-Durance, France
| | - Yann Perrot
- Institut de Radioprotection et de Sûreté Nucléaire, IRSN, PSE-SANTE/SDOS/LDRI, 92262 Fontenay-aux-Roses, France
| | - Myriam Richaud
- IBMM, University of Montpellier, CNRS, ENSCM, 34093 Montpellier, France
| | - Tanima SenGupta
- Section of Clinical Molecular Biology (EpiGen), Akershus University Hospital, 1478 Lørenskog, Norway
| | - Mikaël Cardot-Martin
- Institut de Radioprotection et de Sûreté Nucléaire, IRSN, PSE-SANTE/SDOS/LMDN, Cadarache, 13115 Saint-Paul-lez-Durance, France
| | - Pascal Pedini
- Aix Marseille University, CNRS, EFS, ADES, 13288 Marseille, France
| | | | - Hilde Nilsen
- Section of Clinical Molecular Biology (EpiGen), Akershus University Hospital, 1478 Lørenskog, Norway
- Department of Microbiology, Oslo University Hospital, 0372 Oslo, Norway
| | - Simon Galas
- IBMM, University of Montpellier, CNRS, ENSCM, 34093 Montpellier, France
| | - Christelle Adam-Guillermin
- Institut de Radioprotection et de Sûreté Nucléaire, IRSN, PSE-SANTE/SDOS/LMDN, Cadarache, 13115 Saint-Paul-lez-Durance, France
| |
Collapse
|
12
|
Pedini P, Baudey JB, Basire A, Chiaroni J, Hubert L, Picard C. Evaluation of a new complement-dependent lymphocytotoxicity cross match method using an automated cell counter, the NucleoCounter® NC-3000™. HLA 2023; 101:647-659. [PMID: 37015889 DOI: 10.1111/tan.15044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2022] [Revised: 03/15/2023] [Accepted: 03/20/2023] [Indexed: 04/06/2023]
Abstract
Complement-dependent lymphocytotoxicity cross match (CDC-XM) is the ultimate test of donor/recipient compatibility prior to organ transplantation. This test is based on cell viability, evaluated under fluorescence microscopy by an operator after proper staining. The determination of the positivity threshold may vary depending on the operator. We developed a new method in which the final step of determining cell viability is automated using the NC-3000™ (Chemometec®), an image cytometer able to precisely determine the percentage of dead/live cells in a suspension. After T and B donor cells isolation by negative selection, complement-dependent lysis was performed in macrovolumes in a PCR plate. Then, cell viability was measured by the NC-3000™. The sensitivity and routine CDC-XM results of this new method were compared to those of CDC-XM reference method using Terasaki plates. The sensitivity of CDC-XM expressed in the ASHI scoring system of this method was similar to the reference method results for a dilution range of the positive controls. Similarly, the results of the new method were comparable in a clinical situation to those obtained with the reference method after a study of 10 cross-matches, of which 5 cross-matches with DSA were positive and five cross-matches without DSA were negative. Moreover, ASHI scores were similar to those obtained using the reference method, and the mortality percentage was reproducible (CV < 15%). The assessment of cell viability by the NC-3000™ is easy to perform and highly reproducible but requires CDC-XM to be performed by the macrovolume method. The determination of a precise percentage of viability/mortality by the automation excludes operator variability and allows a better understanding of results close to the decision threshold.
Collapse
Affiliation(s)
- Pascal Pedini
- EFS PACA- Corse, Marseille, France
- UMR 7268 ADÉS Aix-Marseille Université/EFS/CNRS, Marseille, France
| | | | | | - Jacques Chiaroni
- EFS PACA- Corse, Marseille, France
- UMR 7268 ADÉS Aix-Marseille Université/EFS/CNRS, Marseille, France
| | - Lucas Hubert
- EFS PACA- Corse, Marseille, France
- UMR 7268 ADÉS Aix-Marseille Université/EFS/CNRS, Marseille, France
| | - Christophe Picard
- EFS PACA- Corse, Marseille, France
- UMR 7268 ADÉS Aix-Marseille Université/EFS/CNRS, Marseille, France
| |
Collapse
|
13
|
Pedini P, Coiffard B, Casas S, Fina F, Boutonnet-Rodat A, Baudey J, Basire A, Frassati C, Chiaroni J, Gaubert M, Picard C. Clinical Relevance of Donor-Derived Cell-Free Dna and Fragment Size Analysis During the First Month after Lung Transplantation. J Heart Lung Transplant 2023. [DOI: 10.1016/j.healun.2023.02.1400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
14
|
Picard C, Frassati C, Cherouat N, Maioli S, Moskovtchenko P, Cherel M, Chiaroni J, Pedini P. New methods for the quantification of mixed chimerism in transplantation. Front Immunol 2023; 14:1023116. [PMID: 36742303 PMCID: PMC9892455 DOI: 10.3389/fimmu.2023.1023116] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Accepted: 01/05/2023] [Indexed: 01/20/2023] Open
Abstract
Background Quantification of chimerism showing the proportion of the donor in a recipient is essential for the follow-up of hematopoietic stem cell transplantation but can also be useful to document an immune tolerance situation after solid organ transplantation. Historically, chimerism has been quantified from genomic DNA, but with technological advances, chimerism from donor-derived cell-free DNA seems particularly relevant in solid organ transplantation. Methods The reference method was until recently the short tandem repeat technique, but new innovative techniques as digital PCR (dPCR) and NGS, have revolutionized the quantification of chimerism, such as the so-called microchimerism analysis. After a short review of chimerism methods, a comparison of chimerism quantification data for two new digital PCR systems (QIAcuity™ dPCR (Qiagen®) and QuantStudio Absolute Q (ThermoFisher®) and two NGS-based chimerism quantification methods (AlloSeq HCT™ (CareDx®) and NGStrack™ (GenDX®)) was performed. Results These new methods were correlated and concordant to routinely methods (r²=0.9978 and r²=0.9974 for dPCR methods, r²=0.9978 and r²=0.9988 for NGS methods), and had similar high performance (sensitivity, reproductibility, linearity). Conclusion Finally, the choice of the innovative method of chimerism within the laboratory does not depend on the analytical performances because they are similar but mainly on the amount of activity and the access to instruments and computer services.
Collapse
Affiliation(s)
- Christophe Picard
- Immunogenetic Laboratory, EFS PACC, Marseille, France,CNRS, EFS, ADES, Aix Marseille Université, Marseille, France
| | - Coralie Frassati
- Immunogenetic Laboratory, EFS PACC, Marseille, France,*Correspondence: Pascal Pedini, ; Coralie Frassati,
| | | | | | | | | | - Jacques Chiaroni
- Immunogenetic Laboratory, EFS PACC, Marseille, France,CNRS, EFS, ADES, Aix Marseille Université, Marseille, France
| | - Pascal Pedini
- Immunogenetic Laboratory, EFS PACC, Marseille, France,CNRS, EFS, ADES, Aix Marseille Université, Marseille, France,*Correspondence: Pascal Pedini, ; Coralie Frassati,
| |
Collapse
|
15
|
Pedini P, Coiffard B, Cherouat N, Casas S, Fina F, Boutonnet A, Baudey JB, Aho P, Basire A, Simon S, Frassati C, Chiaroni J, Reynaud-Gaubert M, Picard C. Clinical relevance of cell-free DNA quantification and qualification during the first month after lung transplantation. Front Immunol 2023; 14:1183949. [PMID: 37180126 PMCID: PMC10174290 DOI: 10.3389/fimmu.2023.1183949] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Accepted: 04/04/2023] [Indexed: 05/15/2023] Open
Abstract
Background Many studies have reported the relevance of donor-derived cfDNA (dd-cfDNA) after lung transplantation (LTx) to diagnose and monitor acute rejection (AR) or chronic rejection or infection (INF). However, the analysis of cfDNA fragment size has not been studied. The aim of this study was to determine the clinical relevance of dd-cfDNA and cfDNA size profiles in events (AR and INF) during the first month after LTx. Methods This prospective, single-center study includes 62 LTx recipients at the Marseille Nord Hospital, France. Total cfDNA quantification was performed by fluorimetry and digital PCR, dd-cfDNA by NGS (AlloSeq cfDNA-CareDX®), and the size profile by BIABooster (Adelis®). A bronchoalveolar lavage and transbronchial biopsies at D30 established the following groups: not-injured and injured graft (AR, INF, or AR+INF). Results Quantification of total cfDNA was not correlated with the patient's status at D30. The percentage of dd-cfDNA was significantly higher for injured graft patients at D30 (p=0.0004). A threshold of 1.72% of dd-cfDNA correctly classified the not-injured graft patients (negative predictive value of 91.4%). Among recipients with dd-cfDNA >1.72%, the quantification of small sizes (80-120bp) >3.70% identified the INF with high performance (specificity and positive predictive value of 100%). Conclusion With the aim of considering cfDNA as a polyvalent non-invasive biomarker in transplantation, an algorithm combining the quantification of dd-cfDNA and small sizes of DNA may significantly classify the different types of allograft injuries.
Collapse
Affiliation(s)
- Pascal Pedini
- Immunogenetics Laboratory, Etablissement Français du Sang, Marseille, France
- ADES UMR, Aix Marseille Univ, Marseille, France
- *Correspondence: Pascal Pedini,
| | - Benjamin Coiffard
- Aix-Marseille University, Lung Transplant Department, APHM, Marseille, France
| | - Nicem Cherouat
- Immunogenetics Laboratory, Etablissement Français du Sang, Marseille, France
| | - Sylvia Casas
- Medical Direction, CareDx, Brisbane, CA, United States
| | | | | | | | - Printil Aho
- Immunogenetics Laboratory, Etablissement Français du Sang, Marseille, France
| | - Agnes Basire
- Immunogenetics Laboratory, Etablissement Français du Sang, Marseille, France
| | - Sophie Simon
- Immunogenetics Laboratory, Etablissement Français du Sang, Marseille, France
| | - Coralie Frassati
- Immunogenetics Laboratory, Etablissement Français du Sang, Marseille, France
| | - Jacques Chiaroni
- Immunogenetics Laboratory, Etablissement Français du Sang, Marseille, France
- ADES UMR, Aix Marseille Univ, Marseille, France
| | | | - Christophe Picard
- Immunogenetics Laboratory, Etablissement Français du Sang, Marseille, France
- ADES UMR, Aix Marseille Univ, Marseille, France
| |
Collapse
|
16
|
Pedini P, Hicheri Y, Bertand G, Dettori I, Basire A, Lazaygues C, Chabrières C, Perrin C, Pascal J, Chiaroni J, Renac V, Ladaique P, Vey N, Picard C. A case of platelet transfusion refractoriness in a CD36-negative patient with acute myeloid leukemia: Diagnostic and therapeutic management. Transfusion 2022; 62:2148-2150. [PMID: 36214575 PMCID: PMC9827923 DOI: 10.1111/trf.17093] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2022] [Revised: 07/15/2022] [Accepted: 08/09/2022] [Indexed: 11/07/2022]
Affiliation(s)
- Pascal Pedini
- EFS PACA‐CorseMarseilleFrance,UMR 7268 ADÉS Aix‐Marseille Université/EFS/CNRSMarseilleFrance
| | - Yosr Hicheri
- Department of HematologyInstitut Paoli‐CalmettesMarseilleFrance
| | | | | | | | | | | | | | | | - Jacques Chiaroni
- EFS PACA‐CorseMarseilleFrance,UMR 7268 ADÉS Aix‐Marseille Université/EFS/CNRSMarseilleFrance
| | | | | | - Norbert Vey
- Department of HematologyInstitut Paoli‐CalmettesMarseilleFrance,Aix‐Marseille Univ, Inserm, CNRS, Institut Paoli‐Calmettes, CRCMMarseilleFrance
| | - Christophe Picard
- EFS PACA‐CorseMarseilleFrance,UMR 7268 ADÉS Aix‐Marseille Université/EFS/CNRSMarseilleFrance
| |
Collapse
|
17
|
Pedini P, Baudey JB, Pouymayou K, Falaise C, Ibrahim-Kosta M, Vélier M, Demerle C, Graiet H, Dragutini C, Dombey AM, Chiaroni J, Alessi MC, Picard C. Screening platelet function in blood donors. Transfusion 2022; 62:1643-1651. [PMID: 35748562 PMCID: PMC9543520 DOI: 10.1111/trf.16990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2022] [Revised: 04/25/2022] [Accepted: 04/25/2022] [Indexed: 11/29/2022]
Abstract
Background Transfusion of defective platelets could contribute to the inefficiency of platelet transfusion in preventing or stopping bleeding. Study Design and Methods This single‐center prospective study aimed to determine the prevalence of functional platelet abnormalities in a population of blood donors with a clinical history of bleeding diathesis or with history of hematoma (>4 cm) during blood donation. Donors with positive bleeding screening questionnaire were referred to the reference center for rare platelet diseases at La Timone University Hospital (Marseille) to confirm the bleeding tendency using a more extensive bleeding questionnaire (MCMDMscore) and to assess hemostasis, including a comprehensive platelet analysis. Results One hundred and ninety‐five donors identified based on a history of hematoma and 2434 blood donors were included in the study. Eighty‐eight donors (3.6%) had a bleeding score indicating a potential bleeding disorder. Five donors with a history of hematoma (2.5%) and 15 (17%) donors with a confirmed bleeding score underwent hemostatic analysis, including two men and 18 women with average age of 33.9 years. Minor hemostatic abnormalities were observed in three donors. Two donors exhibited accelerated fibrinolysis with reduced euglobulin lysis time and increased D‐dimer levels in serum. Two donors had a platelet granule defect, without identification of genetic abnormality. Conclusion The bleeding questionnaire proved to be a valuable tool to screen blood donors for potential platelet defects. Platelet dysfunction was rare in the blood donor population assessed. Additional studies are necessary to understand the clinical impact that the transfusion of platelets with qualitative defects has on recipients.
Collapse
Affiliation(s)
- Pascal Pedini
- Immunogenetic Laboratory, EFS PACC, Marseille, France.,Aix Marseille Univ, CNRS, EFS, ADES, Marseille, France
| | | | | | | | | | | | | | - Hajer Graiet
- Immunogenetic Laboratory, EFS PACC, Marseille, France
| | | | | | - Jacques Chiaroni
- Immunogenetic Laboratory, EFS PACC, Marseille, France.,Aix Marseille Univ, CNRS, EFS, ADES, Marseille, France.,Department of Phlebotomy, EFS PACC, Marseille, France
| | - Marie Christine Alessi
- Department of Hematology, CHU Timone, Marseille, France.,Aix Marseille University, Inserm, Inrae, C2VN, Marseille, France
| | - Christophe Picard
- Immunogenetic Laboratory, EFS PACC, Marseille, France.,Aix Marseille Univ, CNRS, EFS, ADES, Marseille, France
| |
Collapse
|
18
|
Massy E, Pedini P, Pollet E, Martin M, Roudier J, Picard C, Balandraud N. Association study between HLA-A, -B, -C, -DRB1 alleles and Psoriatic arthritis in southern France. Hum Immunol 2022; 83:515-520. [DOI: 10.1016/j.humimm.2022.04.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Revised: 03/24/2022] [Accepted: 04/05/2022] [Indexed: 11/27/2022]
|
19
|
Pedini P, Hubert L, Thorrignac T, Denhadji Y, Basire A, Chiaroni J, Ladaique P, Picard C. Comparaison de deux méthodes d’identification des anticorps anti-HLA pour la sélection des produits plaquettaires chez des patients réfractaires aux transfusions. Transfus Clin Biol 2021. [DOI: 10.1016/j.tracli.2021.08.240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
20
|
Pedini P, Graiet H, Laget L, Filosa L, Chatron J, Cherouat N, Chiaroni J, Hubert L, Frassati C, Picard C. Qualitative and quantitative comparison of cell-free DNA and cell-free fetal DNA isolation by four (semi-)automated extraction methods: impact in two clinical applications: chimerism quantification and noninvasive prenatal diagnosis. J Transl Med 2021; 19:15. [PMID: 33407582 PMCID: PMC7788686 DOI: 10.1186/s12967-020-02671-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2020] [Accepted: 12/10/2020] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Non-invasive molecular analysis of cell-free DNA (cfDNA) became a sensitive biomarker for monitoring organ transplantation or for detection of fetal DNA (cffDNA) in noninvasive prenatal test. In this study, we compared the efficiencies of four (semi)-automated cfDNA isolation instruments using their respective isolation kit: MagNA Pure 24 (Roche®), IDEAL (IDSolution®), LABTurbo 24 (Taigen®) and Chemagic 360 (Perkin Elmer®). The cfDNA was isolated from 5 plasma samples and the Rhesus D (RhD)-cffDNA from 5 maternal plasmas. The cfDNA were quantified by digital droplet PCR (ddPCR), BIABooster system and QUBIT fluorometer. The cfDNA fragment size profiles were assessed by BIABooster system. Chimerism were quantified by home-made ddPCR and Devyser NGS kit. RhD-cffDNA in maternal plasma were detected between weeks 14 and 24 of amenorrhea using free DNA Fetal RHD Kit® (Biorad®). RESULTS Statistical tests have shown differences in DNA yield depending on the isolation procedure and quantification method used. Magna Pure isolates smaller cfDNA fragment size than other extraction methods (90% ± 9% vs. 74% ± 8%; p = 0.009). Chimerism was only reliable from LABTurbo 24 extractions using the NGS but not with ddPCR whatever extraction methods. RhD-cffDNA were detected by all isolation methods, although IDEAL and LABTurbo 24 systems seemed more efficient. CONCLUSIONS This comparative study showed a dependency of cfDNA yield depending on isolation procedure and quantification method used. In total, these results suggest that the choice of pre-analytical isolation systems needs to be carefully validated in routine clinical practice.
Collapse
Affiliation(s)
- Pascal Pedini
- Department of Histocompatibility, Établissement Français du Sang PACA-Corse, 149 Bd Baille, 13005, Marseille, France.
| | - Hajer Graiet
- Department of Histocompatibility, Établissement Français du Sang PACA-Corse, 149 Bd Baille, 13005, Marseille, France
| | - Laurine Laget
- Department of Immunohematology, Établissement Français du Sang PACA-Corse, 149 Bd Baille, 13005, Marseille, France
| | - Lugdivine Filosa
- Department of Immunohematology, Établissement Français du Sang PACA-Corse, 149 Bd Baille, 13005, Marseille, France
| | - Jade Chatron
- Department of Histocompatibility, Établissement Français du Sang PACA-Corse, 149 Bd Baille, 13005, Marseille, France
| | - Nicem Cherouat
- Department of Histocompatibility, Établissement Français du Sang PACA-Corse, 149 Bd Baille, 13005, Marseille, France
| | - Jacques Chiaroni
- Department of Immunohematology, Établissement Français du Sang PACA-Corse, 149 Bd Baille, 13005, Marseille, France
- UMR 7268, ADÉS Aix-Marseille Université/EFS, CNRS, 27 Bd Jean Moulin, 13385, Marseille Cedex 05, France
| | - Lucas Hubert
- Department of Histocompatibility, Établissement Français du Sang PACA-Corse, 149 Bd Baille, 13005, Marseille, France
| | - Coralie Frassati
- Department of Histocompatibility, Établissement Français du Sang PACA-Corse, 149 Bd Baille, 13005, Marseille, France
| | - Christophe Picard
- Department of Histocompatibility, Établissement Français du Sang PACA-Corse, 149 Bd Baille, 13005, Marseille, France
- UMR 7268, ADÉS Aix-Marseille Université/EFS, CNRS, 27 Bd Jean Moulin, 13385, Marseille Cedex 05, France
| |
Collapse
|
21
|
Pedini P, Cherouat N, Basire A, Simon S, Budon L, Pourtein M, Grondin S, Moskovtchenko P, Chiaroni J, Michel G, Frassati C, Picard C. Evaluation of Next-Generation Sequencing and Crystal Digital PCR for Chimerism Monitoring of Post-Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 2020; 27:89.e1-89.e10. [PMID: 32980546 DOI: 10.1016/j.bbmt.2020.09.023] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2020] [Revised: 09/15/2020] [Accepted: 09/16/2020] [Indexed: 10/23/2022]
Abstract
Hematopoietic stem cell transplantation (HSCT) is a curative treatment for most hematologic diseases. To evaluate the level of donor engraftment, chimerism must be carefully monitored after HSCT. Short tandem repeats, quantitative PCR (qPCR), and, more recently, digital PCR (dPCR) are widely used to determine the proportions of donor and recipient cells after HSCT. The screening and quantification of chimerism have been evaluated by 2 new methods: a ready-to-use next-generation sequencing (NGS)-based method using the Devyser ChimerismNGS kit and an original combination of the Stilla crystal digital PCR (cdPCR) platform with 3-color multiplexing capacity using GenDX KMRtrack reagents. The genotyping of 4 HSCT pairs by cdPCR using 11 triplex mixes of the GenDX KMRtype kit was consistent at 98.8% with qPCR. Informative samples (n = 20) from 6 donor-recipient pairs and 1 external proficiency test demonstrated the reliability of the results (0.1% to 50%) for the 2 methods. The methods are also highly sensitive (0.1%) and accurate. The chimerism values of the 2 methods are correlated and concordant with those of the reference methods. In addition, the ADVYSER software (Devyser) is user-friendly and well adapted to chimerism monitoring. In conclusion, these 2 innovative methods are easy to perform and user-friendly in all molecular, hematology, and immunogenetic laboratories and allow the genotyping and monitoring of chimerism with high performance and sensitivity.
Collapse
Affiliation(s)
- Pascal Pedini
- Immunogenetic Laboratory, Etablissement Français du Sang Provence-Alpes-Côte d'Azur-Corse, Marseille, France; Aix-Marseille University, CNRS, Etablissement Français du Sang, Anthropologie bio-culturelle-Droit-Ethique-Santé, Marseille, France.
| | - Nicem Cherouat
- Immunogenetic Laboratory, Etablissement Français du Sang Provence-Alpes-Côte d'Azur-Corse, Marseille, France
| | - Agnes Basire
- Immunogenetic Laboratory, Etablissement Français du Sang Provence-Alpes-Côte d'Azur-Corse, Marseille, France
| | - Sophie Simon
- Immunogenetic Laboratory, Etablissement Français du Sang Provence-Alpes-Côte d'Azur-Corse, Marseille, France
| | - Laurène Budon
- Immunogenetic Laboratory, Etablissement Français du Sang Provence-Alpes-Côte d'Azur-Corse, Marseille, France
| | | | - Sandra Grondin
- Immunogenetic Laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, Lyon, France
| | - Philippe Moskovtchenko
- Immunogenetic Laboratory, Etablissement Français du Sang Auvergne-Rhône-Alpes, Lyon, France
| | - Jacques Chiaroni
- Aix-Marseille University, CNRS, Etablissement Français du Sang, Anthropologie bio-culturelle-Droit-Ethique-Santé, Marseille, France
| | - Gérard Michel
- Department of Pediatric Hematology-Oncology, Hôpital Enfants la Timone, Marseille, France
| | - Coralie Frassati
- Immunogenetic Laboratory, Etablissement Français du Sang Provence-Alpes-Côte d'Azur-Corse, Marseille, France; Aix-Marseille University, CNRS, Etablissement Français du Sang, Anthropologie bio-culturelle-Droit-Ethique-Santé, Marseille, France
| | - Christophe Picard
- Immunogenetic Laboratory, Etablissement Français du Sang Provence-Alpes-Côte d'Azur-Corse, Marseille, France; Aix-Marseille University, CNRS, Etablissement Français du Sang, Anthropologie bio-culturelle-Droit-Ethique-Santé, Marseille, France
| |
Collapse
|
22
|
Pedini P, Kouba N, Simon S, Basire A, Fina F, Claire G, Jacques C, Picard C. La digitale PCR: nouvelle technologie de détection et de quantification du chimérisme après allogreffe de cellules souches hématopoïétiques. Transfus Clin Biol 2019. [DOI: 10.1016/j.tracli.2019.06.180] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
23
|
Paul P, Pedini P, Lyonnet L, Di Cristofaro J, Loundou A, Pelardy M, Basire A, Dignat-George F, Chiaroni J, Thomas P, Reynaud-Gaubert M, Picard C. FCGR3A and FCGR2A Genotypes Differentially Impact Allograft Rejection and Patients' Survival After Lung Transplant. Front Immunol 2019; 10:1208. [PMID: 31249568 PMCID: PMC6582937 DOI: 10.3389/fimmu.2019.01208] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2019] [Accepted: 05/13/2019] [Indexed: 01/10/2023] Open
Abstract
Fc gamma receptors (FcγRs) play a major role in the regulation of humoral immune responses. Single-nucleotide polymorphisms (SNPs) of FCGR2A and FCGR3A can impact the expression level, IgG affinity and function of the CD32 and CD16 FcγRs in response to their engagement by the Fc fragment of IgG. The CD16 isoform encoded by FCGR3A [158V/V] controls the intensity of antibody-dependent cytotoxic alloimmune responses of natural killer cells (NK) and has been identified as a susceptibility marker predisposing patients to cardiac allograft vasculopathy after heart transplant. This study aimed to investigate whether FCGR2A and FCGR3A polymorphisms can also be associated with the clinical outcome of lung transplant recipients (LTRs). The SNPs of FCGR2A ([131R/H], rs1801274) and FCGR3A ([158V/F], rs396991) were identified in 158 LTRs and 184 Controls (CTL). The corresponding distribution of genotypic and allelic combinations was analyzed for potential links with the development of circulating donor-specific anti-HLA alloantibodies (DSA) detected at months 1 and 3 after lung transplant (LTx), the occurrence of acute rejection (AR) and chronic lung allograft dysfunction (CLAD), and the overall survival of LTRs. The FCGR3A [158V/V] genotype was identified as an independent susceptibility factor associated with higher rates of AR during the first trimester after LTx (HR 4.8, p < 0.0001, 95% CI 2.37-9.61), but it could not be associated with the level of CD16- mediated NK cell activation in response to the LTR's DSA, whatever the MFI intensity and C1q binding profiles of the DSA evaluated. The FCGR2A [131R/R] genotype was associated with lower CLAD-free survival of LTRs, independently of the presence of DSA at 3 months (HR 1.8, p = 0.024, 95% CI 1.08-3.03). Our data indicate that FCGR SNPs differentially affect the clinical outcome of LTRs and may be of use to stratify patients at higher risk of experiencing graft rejection. Furthermore, these data suggest that in the LTx setting, specific mechanisms of humoral alloreactivity, which cannot be solely explained by the complement and CD16-mediated pathogenic effects of DSA, may be involved in the development of acute and chronic lung allograft rejection.
Collapse
Affiliation(s)
- Pascale Paul
- Department of Hematology, Hopital de la Conception, INSERM CIC-1409, Assistance Publique-Hôpitaux Marseille (AP-HM), Marseille, France.,INSERM 1263, INRA, C2VN, Aix-Marseille Université (AMU), INSERM, Marseille, France
| | - Pascal Pedini
- Établissement Français du Sang PACA-Corse 13005, Marseille, France
| | - Luc Lyonnet
- Department of Hematology, Hopital de la Conception, INSERM CIC-1409, Assistance Publique-Hôpitaux Marseille (AP-HM), Marseille, France
| | - Julie Di Cristofaro
- "Biologie des Groupes Sanguins", UMR 7268 ADÉS Aix-Marseille Université/EFS/CNRS, Marseille, France
| | - Anderson Loundou
- Département de santé Publique - EA 3279, Assistance Publique-Hôpitaux Marseille (AP-HM), Aix-Marseille Université, Marseille, France
| | - Mathieu Pelardy
- Établissement Français du Sang PACA-Corse 13005, Marseille, France
| | - Agnes Basire
- Établissement Français du Sang PACA-Corse 13005, Marseille, France
| | - Françoise Dignat-George
- Department of Hematology, Hopital de la Conception, INSERM CIC-1409, Assistance Publique-Hôpitaux Marseille (AP-HM), Marseille, France.,INSERM 1263, INRA, C2VN, Aix-Marseille Université (AMU), INSERM, Marseille, France
| | - Jacques Chiaroni
- Établissement Français du Sang PACA-Corse 13005, Marseille, France.,"Biologie des Groupes Sanguins", UMR 7268 ADÉS Aix-Marseille Université/EFS/CNRS, Marseille, France
| | - Pascal Thomas
- Service de Chirurgie Thoracique et Transplantation Pulmonaire, CHU Nord Assistance Publique-Hôpitaux Marseille (AP-HM), Aix-Marseille Université, Marseille, France
| | - Martine Reynaud-Gaubert
- Service de Pneumologie et Transplantation Pulmonaire, CHU Nord Assistance Publique-Hôpitaux Marseille (AP-HM) - IHU Méditerranée Infection Aix-Marseille-Université, Marseille, France
| | - Christophe Picard
- Établissement Français du Sang PACA-Corse 13005, Marseille, France.,"Biologie des Groupes Sanguins", UMR 7268 ADÉS Aix-Marseille Université/EFS/CNRS, Marseille, France
| |
Collapse
|
24
|
Romanet P, Guerin C, Pedini P, Essamet W, Castinetti F, Sebag F, Roche P, Cascon A, Tischler AS, Pacak K, Barlier A, Taïeb D. Pathological and Genetic Characterization of Bilateral Adrenomedullary Hyperplasia in a Patient with Germline MAX Mutation. Endocr Pathol 2017; 28:302-307. [PMID: 27838885 PMCID: PMC6287616 DOI: 10.1007/s12022-016-9460-5] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
In recent years, familial pheochromocytoma (PHEO) with germline mutations in the MAX (MYC associated factor X) gene has been reported in a few cases. Here, we investigated a 25-year-old patient with multiple PHEOs associated with a non-sense germline MAX mutation. Preoperative 18F-FDOPA PET/CT revealed bilateral adrenal involvement with multiple tumors. In addition, both adrenal glands were found to have diffuse or nodular adrenal medullary hyperplasia (AMH), a histopathological feature previously described as a precursor of MEN2- and SDHB-related PHEOs but not MAX. After bilateral adrenalectomy, different paraffin-embedded and frozen samples were analyzed for allelic imbalances of the MAX gene using allelic quantification by pyrosequencing. The expression of the protein MAX was studied by immunohistochemistry. All PHEOs but also nodular AMH exhibited a loss of the normal allele. By contrast, the diffuse AMH did not show loss-of-heterozygosity. Nevertheless, immunohistochemistry demonstrated loss of protein MAX expression in all samples including diffuse hyperplasia, suggesting a causative role of MAX mutation for both PHEOs and AMH. The present case shows that both nodular and diffuse AMH belongs to the spectrum of MAX-related disease. These data support the possible continuum between nodular AMH and PHEO, expanding the qualification of micro-PHEO to nodular AMH.
Collapse
Affiliation(s)
- Pauline Romanet
- Laboratory of Molecular Biology, Aix Marseille University CNRS, CRN2M, Marseille, France & APHM Conception, 13385, Marseille, France
| | - Carole Guerin
- Department of Endocrine Surgery, Aix-Marseille University Marseille, France & APHM Conception, 13284, Marseille, France
| | - Pascal Pedini
- Laboratory of Molecular Biology, Aix Marseille University CNRS, CRN2M, Marseille, France & APHM Conception, 13385, Marseille, France
| | - Wassim Essamet
- APHM Timone Department of Neuropathology, Marseille, France
| | - Frédéric Castinetti
- Department of Endocrinology, Aix Marseille University, CNRS, CRN2M, Marseille, France & APHM Conception, Marseille, France
| | - Fréderic Sebag
- Department of Endocrine Surgery, Aix-Marseille University Marseille, France & APHM Conception, 13284, Marseille, France
| | - Philippe Roche
- Integrative Structural & Chemical Biology (iSCB) & INT-3D Molecular Modeling Platform, Cancer Research Centre of Marseille, CNRS UMR7258; INSERM U1068; Institut Paoli Calmettes; Aix-Marseille University, UM105, Marseille, France
| | - Alberto Cascon
- Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre and Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain
| | - Arthur S Tischler
- Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, MA, USA
| | - Karel Pacak
- Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD), National Institutes of Health, Bethesda, MD, 20892, USA
| | - Anne Barlier
- Laboratory of Molecular Biology, Aix Marseille University CNRS, CRN2M, Marseille, France & APHM Conception, 13385, Marseille, France
| | - David Taïeb
- Department of Nuclear Medicine, La Timone University Hospital & CERIMED & Inserm UMR1068 Marseille Cancerology Research Center, Institut Paoli-Calmettes, Aix Marseille University, 264 Rue Saint-Pierre, 13385, Marseille, France.
| |
Collapse
|